Literature DB >> 18053068

Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations.

Terry J Hamblin1, Zadie A Davis, David G Oscier.   

Abstract

The choice of 98% sequence homology for immunoglobulin heavy chains to distinguish between mutated and unmutated versions of chronic lymphocytic leukaemia (CLL) was arbitrary and was chosen to account for supposed polymorphisms. Some authors chose 97% or even 95%. This study examined survival curves for cohorts of patients with varying degrees of sequence homology. All patients with <97% homology behaved as if mutated. Those with 97-98% homology were more aggressive than the mutated cases, but less aggressive than those with >98% homology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18053068     DOI: 10.1111/j.1365-2141.2007.06928.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Authors:  Panagiotis Baliakas; Andreas Agathangelidis; Anastasia Hadzidimitriou; Lesley-Ann Sutton; Eva Minga; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao-Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles C Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin E Smedby; Lone Bredo Pedersen; Denis Moreno; Kirsten Van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie-Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian H Geisler; Anton W Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane F Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113

2.  The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Authors:  Preetesh Jain; Graciela M Nogueras González; Rashmi Kanagal-Shamanna; Uri Rozovski; Nawid Sarwari; Constantine Tam; William G Wierda; Philip A Thompson; Nitin Jain; Rajyalakshmi Luthra; Andres Quesada; Gabriela Sanchez-Petitto; Alessandra Ferrajoli; Jan Burger; Hagop Kantarjian; Jorge Cortes; Susan O'Brien; Michael J Keating; Zeev Estrov
Journal:  Br J Haematol       Date:  2017-11-21       Impact factor: 6.998

3.  Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.

Authors:  Philippe Szankasi; David W Bahler
Journal:  J Mol Diagn       Date:  2010-01-28       Impact factor: 5.568

4.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Authors:  Douglas E Gladstone; Lode Swinnen; Yvette Kasamon; Amanda Blackford; Christopher D Gocke; Constance A Griffin; Javier Bolanos Meade; Richard J Jones
Journal:  Leuk Lymphoma       Date:  2011-08-18

Review 6.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

7.  Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.

Authors:  Pavlina Janovska; Lucie Poppova; Karla Plevova; Hana Plesingerova; Martin Behal; Marketa Kaucka; Petra Ovesna; Michaela Hlozkova; Marek Borsky; Olga Stehlikova; Yvona Brychtova; Michael Doubek; Michaela Machalova; Sivasubramanian Baskar; Alois Kozubik; Sarka Pospisilova; Sarka Pavlova; Vitezslav Bryja
Journal:  Clin Cancer Res       Date:  2015-08-03       Impact factor: 12.531

8.  FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.

Authors:  Fu Jun Li; Shouluan Ding; Jicun Pan; Mikhail A Shakhmatov; Elena Kashentseva; Jiongru Wu; Yufeng Li; Seng-jaw Soong; Nicholas Chiorazzi; Randall S Davis
Journal:  Blood       Date:  2008-02-26       Impact factor: 22.113

9.  Immunoglobulin gene repertoire in chronic lymphocytic leukemia: insight into antigen selection and microenvironmental interactions.

Authors:  Efterpi Kostareli; Maria Gounari; Andreas Agathangelidis; Kostas Stamatopoulos
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-08-09       Impact factor: 2.576

10.  Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.

Authors:  Hana Plešingerová; Pavlína Janovská; Archana Mishra; Lucie Smyčková; Lucie Poppová; Antonín Libra; Karla Plevová; Petra Ovesná; Lenka Radová; Michael Doubek; Šárka Pavlová; Šárka Pospíšilová; Vítězslav Bryja
Journal:  Haematologica       Date:  2017-11-09       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.